Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05648968 · ClinicalTrials.gov registry record · Phase 3

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

A Phase 3 study of Warm Autoimmune Hemolytic Anemia (wAIHA), sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
90
Enrollment target
20
Study locations

NCT05648968 is a Phase 3 study of Warm Autoimmune Hemolytic Anemia (wAIHA) that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 90 participants. The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05648968, a Phase 3 study of Warm Autoimmune Hemolytic Anemia (wAIHA), is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
90 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.

Conditions Studied

Warm Autoimmune Hemolytic Anemia (wAIHA)

Interventions

  • DRUG Placebo
  • BIOLOGICAL Ianalumab

Study Locations (20)

Other

  • Novartis Investigative Site - Caba
  • Novartis Investigative Site - Caba
  • Novartis Investigative Site - Dalian
  • Novartis Investigative Site - Tianjin
  • Novartis Investigative Site - Tianjin
  • Novartis Investigative Site - Créteil
  • Novartis Investigative Site - Lille
  • Novartis Investigative Site - Nantes
  • Novartis Investigative Site - Nice
  • Novartis Investigative Site - Dresden
  • Novartis Investigative Site - Essen
  • Novartis Investigative Site - Giessen

Michigan

  • Michigan Center of Medical Research - Farmington Hills

Minnesota

  • University of Minnesota Med Center - Minneapolis

Washington

  • Fred Hutchinson Cancer Center - Seattle

Buenos Aires

  • Novartis Investigative Site - CABA

Australian Capital Territory

  • Novartis Investigative Site - Garran

Victoria

  • Novartis Investigative Site - Melbourne

Guangdong

  • Novartis Investigative Site - Guangzhou

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2022-12-30
Est. Completion 2028-12-19
Phase Phase 3

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05648968

The ClinicalTrials.gov registry entry for NCT05648968 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Warm Autoimmune Hemolytic Anemia (wAIHA) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05648968 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Michigan, Minnesota.

Frequently Asked Questions

What is clinical trial NCT05648968 about?

NCT05648968 is a clinical study titled "A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia". The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.

What is the current status of trial NCT05648968?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2022-12-30. Estimated completion is 2028-12-19.

What conditions does trial NCT05648968 study?

This clinical trial studies the following conditions: Warm Autoimmune Hemolytic Anemia (wAIHA).

What interventions are being tested in trial NCT05648968?

The interventions under investigation include: Placebo (DRUG), Ianalumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT05648968?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05648968 being conducted?

This trial has 20 study locations across Michigan, Minnesota, Washington, Buenos Aires, Australian Capital Territory. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Warm Autoimmune Hemolytic Anemia (wAIHA)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Warm Autoimmune Hemolytic Anemia (wAIHA)

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.